Rokib Hasan

CEO @ Stealth Biotech | Developing Genomic Medicines Leveraging AI. Inventor, Investor & Entrepreneur

[Rokib Hasan @MRokibHasan]

@Fiona_MIT is the winner 🏆 of the debate IMO and I hope she gets involved in DC’s policy making.

[Rokib Hasan @MRokibHasan]

spicy and engaging debate on China biotech and US competitiveness organized by @endpts

@PeterKolchinsky and @jrkelly made the participation worthwhile! 😃

[Rokib Hasan @MRokibHasan]

@sumukhsridhara @kkteily @patio11 Thanks and that would be excellent!

Multiple RUVs adds up costs and other complexities.

[Rokib Hasan @MRokibHasan]

@kkteily @patio11 Yes, this is the real blocker. There should be an option for withdrawal when it reaches to a certain number, let’s say $50K without closing the RUV. Any options to make it happen @sumukhsridhara? Thanks!

[Rokib Hasan @MRokibHasan]

@jrkelly @eperlste Now I should have a ticket!

[Rokib Hasan @MRokibHasan]

@RecursionChris @_DimensionCap Congrats!

[Reuters @Reuters]

Nvidia CEO Jensen Huang met former Sega CEO Shoichiro Irimajiri and game designer Yu Suzuki in Tokyo to thank them for a $5 million investment in 1995 that saved Nvidia from bankruptcy after the company failed to deliver a chip Sega had ordered

[Rokib Hasan @MRokibHasan]

@nejatian @johanhuynhh One of the best comment from you Kaz! 😂

[Albert Bourla @AlbertBourla]

Only in America could a scientist from Greece rise to lead one of the world's great scientific companies. I have never taken that for granted, and I think about it even more as America turns 250.

This country has always had a gift for making bold bets that changed the world. The moon landing, the internet, the Human Genome Project. These milestones and so many others came from generations of Americans who chose to invest in science and a belief in a brighter future.

Today, America faces a choice once again.

New tools in biology, from how we design medicines to how we manufacture them, have already expanded what is possible for patients. AI will shape what comes next in ways we are only beginning to see.

Tools alone don’t determine outcomes. It requires investing in innovation. It requires committing to shaping future opportunities. The coming decade will determine where great new discoveries occur and where the most ambitious scientists build their life's work.

I want the answer to be here. Other nations have serious scientific ambition, and I welcome it. Competition never scared America. It has always made us better. You don’t win races by trying to hold others back. You win by running faster, running harder.

America’s opportunity is to continue leading by investing more, building more and moving faster. Pfizer will continue doing its part. We were founded in New York in 1849, and we have been competing and betting on American science ever since. We are driven by a single purpose: delivering breakthroughs that change patients' lives.

My wish for America's 250th birthday is simple. Let us choose, once again, to bet on ourselves – and on science. No nation has ever done it better.

🇺🇸 #A250

[Rokib Hasan @MRokibHasan]

@chamath Exciting to see you as an operator again and congrats!

[Robert Nelsen @rtnarch]

Re ex-USA copycats, we need free markets, not bans. However, for blatant cases, because patents move so slowly, there can be a role for government to incentivize economic settlement by advantaging the USA company administratively. This is where we need creativity and discussion.

Maybe we give harmed companies a true regulatory speed advantage-automatic fastest review. Or we let firms that can show administrative harm (not in patent courts) capitalize their NOL’s. Or if there is a protest to a pharma deal that is a blatant foreign rip off, they must buy a voucher from the harmed company to proceed (all administrative, no court)

The first people to copy Beam and Prime were not China— they were USA start-ups and Pharma, who will pay eventually. Pharma has been copying biotech forever.

But a system that enables Pharma or others to cherry-pick foreign blatant copies with no economic cost is also not fair, as it essentially dries up money for USA fundamental innovation.

We are absolutely reducing our investing in platforms because we are starting to get eviscerated before we get to the finish line.

Ultimately, maybe it is an evolution of the market, but there is a National Interest in preserving biotech innovation, the USA controls almost entirely the market for drugs, and having some system that advantages those who take risks for long term innovation is good policy.

[Rokib Hasan @MRokibHasan]

“It’s good for consumers” was the exact excuse when we let our manufacturing base hollowed out… hope we don’t do the same with “it’s good for patients” logic. I’ve strong believe and trust in the scientists and startups here in USA whose success would be great for patients too.

[Rokib Hasan @MRokibHasan]

Well, fund like RA and RTW have a fiduciary duty to make money for their LPs. They are doing their job.

Now, US lawmakers need to do theirs.

Offshoring our R&D is a direct national security risk. By funding foreign science over US startups, we:

❌ Kill domestic biotech jobs
❌ Starve our own innovators of capital
❌ Become dangerously dependent on rivals for life-saving medicine

We must invent and build at home! 🇺🇸

If cost is the excuse, tap into the talent and affordability of Middle America. We already made the catastrophic mistake of outsourcing our manufacturing base for cheap goods. Let's not repeat it with our medicine.

[Jason Kelly @jrkelly]

Ugh this sucks @PeterKolchinsky, bad for MA jobs @JakeAuch and bad for US nat sec @sethmoulton, @IAmBiotech. So exhausting that our own VC leaders in biotech are working against US startups and US biotech scientists.

This tactic of offshoring to low cost scientific labor in China is going to fail. US biotech startups are going to prove it, we’re not giving up without a fight.

[Rokib Hasan @MRokibHasan]

@AppleHelix Much needed initiative for the sub $5m seed deals. If some of these companies succeed, it will create the flywheel effect considering the early valuation and ROI potential.

[Rokib Hasan @MRokibHasan]

@kenbwork Love it and congrats @kenbwork & team @LatchBio!

[Andre Watson 🧬 @nanogenomic]

There’s a reason that DNA synthesizers are export-controlled. However, the most concerning applications and sequences are, ironically, not the most obvious. A sensible policy is to screen the users and orgs, more so than the specific sequences being made, as far as threat vectors go.

[Rokib Hasan @MRokibHasan]

@A_May_MD @robdubparker @A_May_MD What makes you think Intellia's mRNA-LNP treatment won't follow the exact same patent-cliff trajectory, eventually making a one-time cure cheaper than a lifetime of chronic management?

Perhaps, time to revisit the COGS of a non-viral mRNA-LNP based treatment?

[Rokib Hasan @MRokibHasan]

@jrkelly @Ginkgo @AAlphaBio Can we have more of these in Boston as well? Thanks!

[NVIDIA Healthcare @NVIDIAHealth]

Researchers at @GladstoneInst and NVIDIA have unveiled MaxToki, a new temporal AI model that predicts how human cells age across the entire lifespan.

- New Therapeutic Targets for Disease: Predicted cardiac pro-aging drivers that were experimentally validated in vivo.
- Scale: Trained on ~175M cells and ~100M cell state trajectories from birth to age 90+.
- Training Speed: Achieved 5x increase in training throughput and 4x increase in achievable microbatch size with NVIDIA BioNeMo.
- Inference speed: Achieved 400x inference acceleration with NVIDIA Megatron-Core.

We’re excited to see how researchers use it to study ways to slow or reverse age-related diseases.
Pre-print link 👇

[Kris Siemionow, MD, PhD @siemionowkris]

🚨 Major boost for US biotech: @WhiteHouse backed @US_FDA proposal for an **optional risk-based Expedited IND pathway** — slashing Phase 1 timelines to first-in-human trials using validated preclinical data.

Reduces duplicative requirements that drive longer/higher-burden US timelines vs. China/Australia (where early trials can be 50-60% cheaper & start in weeks, vs. US delays of months to a year). Saves significant time & money for smaller firms.

#Biotech #FDA